The Latest Breaking News from Pfizer

U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year

Inadequate use of antiviral medication led to avoidable mortality, with Paxlovid underutilized

Pfizer (PFE) is spending its COVID-19 cash flows on meaningful growth avenues. However, given a recent downgrade, should value investors still be excited about this stock? Let’s look at the trends of its financial metrics to get an idea….

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

Rivian’s strong sales results drove the unusual options activity in Friday trading. For those who aren’t enamored with the electric vehicle manufacturer’s business, there are, pardon the pun, other options.

Health officials are endorsing two new vaccines against respiratory syncytial virus (RSV) for older Americans, alongside flu and Covid-19 vaccines, although there are uncertainties about the risks

With the growing prevalence of chronic conditions, an aging population, widespread adoption of digital technologies, and several R&D efforts, the pharmaceutical industry is poised for exponential growth and expansion. So, let’s compare leading pharma stocks AbbVie (ABBV) and Pfizer (PFE) to identify which is a better investment now. Keep reading….

Vaccines to stave off the flu, a new COVID variant and now, respiratory syncytial virus could help avert another tripledemic this fall. Unless the public is too crisis-fatigued to care.

Participants could receive groundbreaking treatment after the Government signed an agreement with a leading pharmaceutical company.